Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CatalYm GmbH logo — Developing innovative immunotherapies to transform cancer pa...

CatalYm GmbH

Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.

Founded 2016 Germany Germany 56 employees Series D Total: $250.00M Biotechnology, Health Care +1

General Information

Company Name CatalYm GmbH
Founded Year 2016
Location Germany Germany
Employees 56
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series D
Business Model B2B, B2B2C
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with CatalYm GmbH. To contact CatalYm GmbH, visit catalym.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CatalYm GmbH compare?

A PDF of CatalYm GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CatalYm GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CatalYm GmbH

CatalYm GmbH, founded in 2016, is a Germany-based company deeply embedded in the Biotechnology and Health Care sectors. The company's mission—"Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems"—captures its commitment to advancing medical treatments through revolutionary approaches.

CatalYm focuses on the development of antibodies that target a placental factor, which is often overproduced in various tumors. This innovative approach positions CatalYm as a leader in creating immunotherapies with the potential to dramatically improve outcomes for cancer patients globally.

Recently, the company secured a substantial $150.00M Series D investment on 16 July 2024. The financing round saw participation from notable investors including Canaan Partners, Forbion, Gilde Healthcare, Novartis, Bioqube Ventures, Jeito Capital, Omega Funds, Vesalius Biocapital, and Brandon Capital, underscoring the strong confidence in CatalYm's innovative platform and market potential.

Business keywords: Immunotherapy, Cancer Treatment, Oncology, Antibody Development, Tumor Microenvironment, GDF-15 Targeting, Solid Tumors, Neutralizing Antibodies, Immune System Engagement, Placental Factor Overproduction, CT-002 Program, Clinical Proof-of-Concept, Therapeutic Innovation, Tumor-Specific Treatment

Services & Products

Development of immunotherapies targeting GDF-15
Conducting clinical trials for cancer treatment
Advancing drug candidates for cachexia associated with cancer

Target Customers

Oncologists Cancer Centers Pharmaceutical Companies Healthcare Providers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $150.00M 9
Brandon Capital Partners Novartis Venture Fund Forbion
Brandon Capital Partners, Novartis Venture Fund +7
01 Jul 2024
Series C €50.00M 8
Bayern Kapital Brandon Capital Partners Novartis Venture Fund
Bayern Kapital, Brandon Capital Partners +6
01 Nov 2022
Series B €50.00M 1
Vesalius Biocapital
Vesalius Biocapital
01 Nov 2020
Seed Undisclosed -
01 Aug 2016

Latest News

View All
Despite faltering VC funding in Europe, healthtech made a comeback in Q3 — Eu-startups
Despite faltering VC funding in Europe, healthtech made a comeback in Q3
Eu-startups Oct 21, 2024

CatalYm GmbH Alternatives & Competitors

View All Alternatives
CatalYm GmbH vs
Bicara Therapeutics
Bicara Therapeutics United States

Pioneering bifunctional antibodies for targeted tumor modulation

IPO
123 employees
Biopharma, Biotechnology
Compare CatalYm GmbH vs Bicara Therapeutics
CatalYm GmbH vs
OXFORD VACMEDIX UK LIMITED
OXFORD VACMEDIX UK LIMITED United Kingdom

Developing therapeutic cancer vaccines using ROP technology

Series A
8 employees
Health Care, Health and Wellness
Compare CatalYm GmbH vs OXFORD VACMEDIX UK LIMITED
CatalYm GmbH vs
NBE-Therapeutics AG
NBE-Therapeutics AG Switzerland

Next generation antibody drug conjugates

Series C
48 employees
Biotechnology, Health Care
Also compare with: CatalYm GmbH vs Xilio Therapeutics, Inc. Xilio Therapeutics, Inc. CatalYm GmbH vs Pyxis Oncology Pyxis Oncology View all alternatives

FAQ About CatalYm GmbH

Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.
CatalYm GmbH was founded in 2016.
CatalYm GmbH is headquartered in Germany.
CatalYm GmbH operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Immunotherapy, Cancer Treatment, Oncology and Antibody Development. Its customers include Oncologists, Cancer Centers and Pharmaceutical Companies.
CatalYm GmbH has a B2B and B2B2C business model. Its revenue comes from Licensing, Product Sales and Performance Based.
CatalYm GmbH has approximately 56 employees.
CatalYm GmbH has completed 4 funding rounds, raising a total of $250.00M. The latest funding stage is Series D.
CatalYm GmbH offers: Development of immunotherapies targeting GDF-15, Conducting clinical trials for cancer treatment, Advancing drug candidates for cachexia associated with cancer.
Top alternatives and competitors to CatalYm GmbH include Bicara Therapeutics, OXFORD VACMEDIX UK LIMITED, NBE-Therapeutics AG, Imvax, Inc., Crossbow Therapeutics, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CatalYm GmbH and Bicara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CatalYm GmbH, https://bouncewatch.com/company/catalym, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes